Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30311288 | 1.00 | AKR1B1 (0.61) | AKR1B1EGFRKDM4EMAPTTSHR | |
| Methane SCHEMBL9292057 | 0.98 | AKR1B1 (0.59) | AKR1B1EGFRKDM4EMAPTTSHR | |
| Phenol SCHEMBL2808100 | 0.93 | AKR1B1 (0.58) | AKR1B1EGFRKDM4EMAPTTSHR | |
| SCHEMBL7606591 | 0.90 | AKR1B1 (0.50) | AKR1B1EGFRKDM4EMAPTTSHR | |
| SCHEMBL1554320 | 0.87 | KDM4E (0.53) | EGFRKDM4EMAPTTSHRLMNA | |
| SCHEMBL25285645 | 0.85 | IAPP (0.51) | AKR1B1EGFRKDM4EMAPTLMNA | |
| SCHEMBL1958849 | 0.84 | AKR1B1 (0.55) | AKR1B1KDM4ETSHRLMNAALDH1A1 | |
| SCHEMBL2228365 | 0.83 | AKR1B1 (0.65) | AKR1B1TSHRCYP2D6HIF1AHSPA5 | |
| SCHEMBL29349625 | 0.83 | AKR1B1 (0.65) | AKR1B1TSHRCYP2D6HIF1AHSPA5 | |
| SCHEMBL21647807 | 0.83 | AKR1B1 (0.44) | AKR1B1EGFRKDM4EMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 565 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108997122-B | 3-aryl-4-alkoxy benzyl ether derivative and preparation method and application thereof | 南方医科大学 | 2020-12-29 | — | — | CN | claimed |
| CN-109134765-A | A kind of polyisobutene and the graft copolymer of polyisoprene and preparation method thereof | 北京化工大学 | 2019-01-04 | — | — | CN | claimed |
| CN-108997122-A | 3- aryl -4- alkoxy benzyl oxide derivative and its preparation method and application | 南方医科大学 | 2018-12-14 | — | — | CN | claimed |
| CN-108929226-A | A method of preparing benzoyl formic acid ester derivant | 广东工业大学 | 2018-12-04 | — | — | CN | claimed |
| CN-106606465-A | Spot removal cream and preparation method thereof | 田川 | 2017-05-03 | — | — | CN | claimed |
| US-20050192411-A1 | Triazine compounds, polymers comprising triazine structural units, and method | GENERAL ELECTRIC CO. | 2005-09-01 | — | — | US | claimed |
| EP-1560817-A1 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | Reddy US Therapeutics, Inc. (US) | 2005-08-10 | — | — | EP | claimed |
| EP-1423372-A2 | TRIAZINE COMPOUNDS, POLYMERS COMPRISING TRIAZINE STRUCTURAL UNITS, AND PROCESSES FOR THE PREPARATION OF THESE POLYMERS | GENERAL ELECTRIC COMPANY (US) | 2004-06-02 | — | — | EP | claimed |
| WO-2004026844-A1 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | REDDY US THERAPEUTICS, INC. (US) | 2004-04-01 | — | — | WO | claimed |
| US-20030078347-A1 | Triazine compounds, polymers comprising triazine structural units, and method | GENERAL ELECTRIC COMPANY | 2003-04-24 | — | — | US | claimed |
| WO-2003024939-A2 | TRIAZINE COMPOUNDS POLYMERS COMPRISING TRIAZINE STRUCTURAL UNITS, AND PROCESSES FOR THE PREPARATION OF THESE POLYMERS | GENERAL ELECTRIC COMPANY (US) | 2003-03-27 | — | — | WO | claimed |
| US-6538065-B1 | Polymerizing a hydroxy-terminated polyester intermediate with a carbonate precursor in a two-phase system comprising an aqueous phase and a water-immiscible organic solvent; use as protective coatings; weatherproof, radiation resistance | GENERAL ELECTRIC COMPANY | 2003-03-25 | — | — | US | claimed |
| US-20030050400-A1 | METHOD FOR PREPARING COPOLYESTERCARBONATES AND ARTICLES THEREFROM | GENERAL ELECTRIC COMPANY | 2003-03-13 | — | — | US | claimed |
| US-6197226-B1 | COMPRISING DIPPING RESIN INTO A LIQUID CONTAINING POLAR COMPOUND SELECTED FROM POLAR INORGANIC COMPOUNDS AND POLAR ORGANIC COMPOUNDS AND TINTING RESIN, WHEREIN RESIN IS OBTAINED BY CURING BY POLYMERIZATION A SULFUR CONTAINING COMPOUND | MITSUBISHI GAS CHEMICAL COMPANY (JP) | 2001-03-06 | — | — | US | claimed |
| US-5034493-A | Comprising the reaction product obtained by heating a mixture of a zinc carboxylate, a carboxylic anhydride aknd a phenol or glycidyl ether or ester; colorless; storage stability; fast c uring; optics | NEW JAPAN CHEMICAL CO., LTD. (JP) | 1991-07-23 | — | — | US | claimed |
| US-20260144743-A1 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-05-28 | — | — | US | disclosed |
| EP-4714961-A2 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-0168467-A1 | NOVEL ARYLACETIC ACID DERIVATIVES | PHARMACIA AB (SE) | 1986-01-22 | — | — | EP | disclosed |
| WO-1985003287-A1 | NOVEL ARYLACETIC ACID DERIVATIVES | PHARMACIA AB (SE) | 1985-08-01 | — | — | WO | disclosed |
| EP-0150166-A1 | Novel arylacitic acid derivatives | PHARMACIA AB (SE) | 1985-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | CACNA1E, TMEM109, CACNA1C | AKR1B1 1457/4885EGFR 1775/4885KDM4E 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.